Letters

Methotrexate and bone marrow suppression: Authors' reply

BMJ 2003; 326 doi: https://doi.org/10.1136/bmj.326.7399.1145-d (Published 22 May 2003) Cite this as: BMJ 2003;326:1145
  1. M Sosin, research fellow,
  2. S Whitmarsh, principal pharmacist,
  3. S Handa, consultant haematologist (sunil.handa@swbh.nhs.uk)
  1. Sandwell and West Birmingham NHS Trust, Sandwell Hospital, West Bromwich B71 4HJ
  2. Sandwell and West Birmingham NHS Trust, Sandwell Hospital, West Bromwich B71 4HJ,

    EDITOR—We agree with Grove that bone marrow toxicity is not usually an early complication of methotrexate treatment and that current guidelines recommend more rigorous monitoring of the blood count in the early stages of treatment. Therefore all healthcare professionals who come into contact with …

    View Full Text

    Sign in

    Log in through your institution

    Free trial

    Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
    Sign up for a free trial

    Subscribe